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Abstract 
The long-term performance of prediction scores for venous thromboembolism (VTE) in cancer 
patients has been poorly investigated. We evaluated the discriminatory performance of the Khorana, 
PROTECHT, CONKO, and ONKOTEV scores for the first 3-6 months and for 12 months, and re-
assessed scores after 3-6 months to determine the influence of variations in patients' risk 
classification on performance.  
Retrospective cohort of ambulatory patients with active cancer who were scheduled to receive first 
or new line of chemotherapy. The primary outcome was symptomatic or incidental VTE. 
A total of 776 patients were included of whom 540 (70%) had distant metastases. The time-
dependent c-statistics of Khorana, PROTECHT, CONKO, and ONKOTEV scores at 6 months were 0.61 
(95% CI, 0.56 to 0.66), 0.61 (95% CI, 0.55 to 0.66), 0.60 (95% CI, 0.54 to 0.66), and 0.59 (0.52 to 0.66), 
respectively, with a tendency to decrease during follow-up. None of the scores discriminated 
between high and low risk patients at the conventional 3-point positivity threshold. The use of a 2-
point positivity threshold improved performance of all scores and captured a higher proportion of 
VTE. The accuracy of risk scores re-assessed at 3-6 months was modest. 
The Khorana, PROTECHT, CONKO, and ONKOTEV scores are not sufficiently accurate when used at a 
conventional threshold of 3 points. Performance improves at positivity threshold of 2 points, as 
evaluated in recent randomized studies on VTE prophylaxis. Score accuracy tends to decrease over 
time suggesting the need of periodic re-evaluation to estimate possible variation of risk.  
 
 
Keywords: neoplasms, venous thrombosis, venous thromboembolism, predictive value of tests, 
biomarkers 
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Key points 
 VTE is a frequent complication in patients with cancer, but most of these patients will not 
develop thrombosis during the course of their disease 
 Prediction scores have been developed to identify cancer patients at higher risk of VTE in 
whom the benefits of thromboprophylaxis would not be offset by the risk of bleeding 
 At the conventional 3-point threshold, the Khorana, PROTECHT, CONKO, and ONKOTEV 
scores perform poorly  
 Performance improves at 2-point positivity threshold, but residual VTE risk remains 
substantial 
 Score accuracy decreases over time suggesting the need of periodic re-evaluation  
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Introduction 
Although venous thromboembolism (VTE) represents a frequent complication in patients with cancer 
undergoing chemotherapy, most of these patients will not develop thrombosis during the course of 
their disease [1-2]. Therefore, broad, routine use of pharmacological thromboprophylaxis would 
unnecessarily expose most of these patients to burdensome long-term subcutaneous heparin 
administration as well as to the risk of anticoagulant-related bleeding [3].  
Several studies have attempted to identify cancer patients at higher risk of VTE in whom the 
benefits of thromboprophylaxis would not be offset by the risk of bleeding [4-5]. One of the most 
extensively evaluated VTE risk stratification tools for cancer patients is the score developed by 
Khorana and colleagues, which is calculated by assigning points to the type of tumor, low hemoglobin 
level or use of erythropoietic agents, high body mass index, and high platelet or white blood cell 
count (Supplementary Table 1) [6]. In the derivation study including over 3,000 ambulatory cancer 
patients, the score identified a high-risk group in whom the incidence of VTE was 7% during a mean 
follow-up of 3 months. These findings were replicated in a number of external cohort studies [4,7]. 
Similarly, two recent randomized clinical trials of pharmacological prophylaxis including cancer 
patients at high risk of VTE according to the Khorana score reported a VTE incidence of around 10% 
in patients receiving placebo, which support the use of this score to identify patients at risk of VTE [8-
9]. In contrast, in a large meta-analysis of over 34,000 cancer patients, the incidence of VTE in low or 
intermediate risk groups according to the Khorana score was not negligible, and over half of the 
patients who ultimately developed cancer-associated VTE did not qualify for thromboprophylaxis 
based on their risk score profile [10]. Patients with a low Khorana score were not randomized nor 
prospectively followed in the two recent randomized studies, which leaves unclear how many 
eventually experienced VTE [8-9].  
Efforts have been made to increase the performance of the Khorana score or derive new 
prediction models. For example, the Khorana score could be improved by adding measurement of D-
dimer and soluble P-selectin [11], adding use of gemcitabine or platinum compounds [12], by 
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replacing body mass index with functional status [13], and by adding metastatic disease, vascular 
compression, and previous VTE to the dichotomized Khorana score (Supplementary Table 1)[14]. 
Nonetheless, a recent prospective validation study with 6-month follow-up found that the 
performance of most of these scores was still suboptimal as indicated by low c-statistics [7]. In 
addition, the accuracy of prediction tools for VTE in cancer patients over follow-up periods longer 
than 3 to 6 months has been poorly investigated. Preliminary observations suggest that performance 
decreases after the first weeks of follow-up [7]. Since all these scores include parameters that can 
vary over time, this may ultimately result in changes of patients' risk classification and score 
performance. 
The aims of this study were to compare the discriminatory performance of the Khorana, 
PROTECHT, CONKO, and ONKOTEV scores for the first 3 to 6 months versus 12 months of follow-up, 
and to re-assess all scores after 3 to 6 months to determine variations of patients' risk classification 
and performance of the follow-up score compared to the score calculated at start of chemotherapy. 
In addition, we validated the long-term accuracy of the scores at a 2-point positivity threshold, as 
used in recently completed randomized studies on VTE prophylaxis in patients with cancer [8-9]. 
 
Materials and Methods 
Study population 
We conducted a single-center, retrospective cohort study of patients with recurrent, regionally 
advanced, or metastatic cancer in whom the Khorana, PROTECHT, CONKO, and ONKOTEV scores 
were calculated before the start of a first or new line of chemotherapy. Exclusion criteria were 
ongoing anticoagulant treatment for VTE diagnosed prior to start of chemotherapy or for other 
indications, or use of outpatient thromboprophylaxis during the study. The study was approved by 
the local institutional review board. 
 
Study Outcomes 
6 
 
The primary outcome of the study was symptomatic or incidental VTE, defined as distal or proximal 
deep vein thrombosis (DVT) of the leg, upper extremity DVT, and/or pulmonary embolism (PE) [15]. 
Incidental VTE was defined as VTE detected by imaging tests performed for other reasons than VTE 
suspicion, such as assessment of response to cancer treatment, cancer re-staging or the diagnostic 
work-up of cancer-related complications [16]. 
Secondary outcomes were major bleeding, clinically relevant non-major bleeding, arterial 
thromboembolism, superficial vein thrombosis, and overall mortality [17-18]. 
 
Statistical considerations 
Standard descriptive statistics were used to summarize patient characteristics. We calculated the 
Khorana, PROTECHT, CONKO, and ONKOTEV score before start of chemotherapy and after 3 to 6 
months. Tumor sites were categorized into “low/intermediate”, “high”, and “very-high” risk of VTE 
according to the Khorana score [6]. Patients were followed for the development of VTE up to 1 year 
since the start of chemotherapy. The Khorana score was assessed at the conventional positivity 
threshold of 3 points as well as at the exploratory 2-point threshold. We also evaluated the 
performance of the PROTECT, CONKO, and ONKOTEV scores which are modifications of the Khorana 
score (Supplementary Table 1) [12-14]. We could not assess the CATS score since D-dimer and 
soluble P-selectin are not measured routinely [11] nor the extensive COMPASS-CAT score because 
data on cardiovascular risk factors were not available [19]. 
 Overall discrimination of the scores for PE and/or DVT was assessed with a time-dependent 
c-statistic, while accounting for death not related to VTE as a competing risk (R package concreg). The 
95% confidence intervals were estimated by repeating the analyses in 250 bootstrap samples. The 
cumulative incidence in patients with a high and low risk score was estimated using the cumulative 
incidence function with 95% confidence intervals calculated using Choudhury’s method, considering 
death not related to VTE as a competing risk. Differences between high and low risk patients were 
quantified by calculating subdistribution hazard ratios (SHRs) based on the competing risk regression 
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model of Fine & Gray (R package cmprsk). A multivariable Fine & Gray model was used to assess the 
association of the individual score items with VTE. A sensitivity analysis restricted to symptomatic 
events was performed. Since the proportion of patients for whom the scores could not be calculated 
was low (<3%), we did not use multiple imputation methods. Analyses were performed in R, version 
3.4.4 (R Foundation for Statistical Computing, Vienna, Austria). 
 
Results 
Between January 2011 and July 2017, 887 potentially eligible cancer patients were identified of 
whom 111 (12.5%) were excluded because of ongoing anticoagulant treatment for VTE (N=63), atrial 
fibrillation (N=37), or mechanical heart valve (N=2), or because they did not attend oncological 
follow-up visits after the initial evaluation due to rapid cancer progression (N=48). Baseline 
characteristics of the remaining 776 patients are summarized in Table 1. Mean age was 65 years and 
61% was male. The most frequent tumor types were non-small lung cancer (29%), colorectal cancer 
(29%), and gynecological cancer (11%). The distribution of the risk scores at baseline and at follow-up 
re-assessment is shown in Table 2. 
 
Follow-up and outcomes 
The median overall follow-up duration was 330 days (interquartile range [IQR], 159 to 365). Overall, 
69 patients (8.9%) developed a thrombotic event which was DVT in 28 (3.6%), PE in 20 (2.6%), 
splanchnic DVT in 10 (1.3%), PE with DVT in 6 (0.8%), superficial vein thrombosis in 3 (0.4%), and 
arterial thrombosis in 2 (0.3%). Of the 54 PE, DVT, and PE with DVT, 27 events (50%) were 
symptomatic.  The 3-, 6-, and 12-month cumulative incidences of PE and/or DVT in the competing 
risk analysis were 2.8% (95% CI, 1.8 to 4.2), 5.6% (95% CI, 4.2 to 7.4), and 7.2% (95% CI, 5.5 to 9.2), 
respectively. The median time to PE and/or DVT was 104 days (95% CI, 64 to 172). During follow-up, 
343 patients (44%) died and 5 (0.6%) were lost to follow-up. 
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Performance of baseline risk scores  
The overall discriminatory performance of the baseline scores for PE and/or DVT is shown in Table 3. 
The time-dependent c-statistics of the Khorana, PROTECHT, CONKO, and ONKOTEV scores at 180 
days were 0.61 (95% CI, 0.56 to 0.66), 0.61 (95% CI, 0.55 to 0.66), 0.60 (95% CI, 0.54 to 0.66), and 
0.59 (0.52 to 0.66), respectively (Supplementary Figures 1A-D). The sensitivity analysis restricted to 
symptomatic events yielded comparable results (c-statistics 0.63, 0.62, 0.62, and 0.56 for the 
Khorana, PROTECHT, CONKO, and ONKOTEV scores, respectively). 
Using the conventional positivity threshold of 3 points, the Khorana, PROTECHT, CONKO, and 
ONKOTEV scores classified 12%, 42%, 12%, and 2.6% of patients as high risk (Table 2). The cumulative 
incidence of VTE at 6 months in these high-risk patients was 3.5%, 7.6%, 4.4%, and 15% respectively, 
compared to 6.0%, 4.4%, 5.9%, and 5.4% in the low risk groups. The corresponding SHRs for high vs. 
low risk were 0.58 (95% CI, 0.18 to 0.87), 1.8 (95% CI, 0.98 to 3.3), 0.73 (95% CI, 0.26 to 2.1), and 3.0 
(95% CI, 0.91 to 10) for the Khorana, PROTECHT, CONKO, and ONKOTEV scores, respectively (Figures. 
1A-D). Data for the 12-month study period are presented in Table 3. 
Using the alternative positivity threshold of 2 points, the Khorana, PROTECHT, CONKO, and 
ONKOTEV scores classified 40%, 71%, 39%, and 33% of patients as high risk (Table 2). In these high-
risk groups, the cumulative incidences of PE or DVT at 6 months were 7.7%, 7.8%, 7.3%, and 7.2% 
compared to 4.4%, 0.5%, 4.7%, and 4.8% in patients with a low risk score, respectively. The 
corresponding SHRs for high vs. low risk patients were 1.8 (95% CI, 0.98 to 3.3), 17 (95% CI, 2.3 to 
122), 1.6 (95% CI, 0.89 to 3.0), and 1.5 (95% CI, 0.83 to 2.8) for the Khorana, PROTECHT, CONKO, and 
ONKOTEV scores, respectively (Figures 2A-D). 
In multivariable competing risk analyses, all score items except high platelet count had a 
positive association with PE and/or DVT at 6 months (Supplementary Table 2). The only items that 
met statistical significance were platinum-based chemotherapy in the PROTECHT score (SHR 2.5; 95% 
CI, 1.1 to 6.1) and previous VTE in the ONKOTEV score (SHR 17; 95% CI, 5.2 to 52). 
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Performance of risk scores re-assessed at 3 to 6 months 
Re-assessment of the risk scores was done in 606 of 618 patients who were alive and without 
thrombosis (98%) at a median follow-up of 158 days (IQR, 113 to 179). From this re-assessment until 
the end of follow-up, 15 patients (2.5%) developed a thrombotic event of which 12 events (2.0%) 
were PE and/or DVT. At the conventional positivity threshold of 3 points, the re-assessed Khorana, 
PROTECHT, CONKO, and ONKOTEV scores re-classified 12%, 32%, 12%, and 1% of patients, 
respectively (Supplementary Tables 3A-D). Overall, 10%, 14%, 11%, and 3% of patients were classified 
as being at high risk by the re-assessed Khorana, PROTECHT, CONKO, and ONKOTEV scores. The 
cumulative incidence of PE or DVT at 180 days after re-assessment was 3.3%, 2.4%, 3.0%, and 5.6% in 
patients with a high-risk Khorana, PROTECHT, CONKO, and ONKOTEV score, respectively 
(Supplementary Table 4). These numbers were 1.9%, 2.0%, 1.9%, and 0.70% in those with a low risk 
score, corresponding to SHRs of 1.8 (95% CI, 0.38 to 8.0), 1.2% (95% CI, 0.26 to 5.5), 1.6 (95% CI, 0.34 
to 7.1), and 8.1 (95% CI, 0.93 to 71), respectively.  
 
DISCUSSION 
This study confirms the poor overall discriminatory performance of the Khorana, PROTECHT, CONKO, 
and ONKOTEV scores for the prediction of DVT or PE in patients with cancer receiving chemotherapy. 
When used dichotomously, none of the scores was able to identify a group of patients with a 
significantly higher risk of VTE. Yet, the use of a lower positivity threshold of 2 points was associated 
with improved performance of all scores, but in particular the PROTECHT and CONKO scores. Time-
dependent analysis suggested that scores’ discrimination tends to decrease during follow-up, with 
limited or no value of the scores beyond the first 3 to 6 months. Re-evaluation of the four scores at 3 
to 6 months changed the indication for pharmacological thromboprophylaxis in 12% up to 32% of 
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patients, but the use of a re-assessed score is questionable because of the low risk of DVT or PE in 
the following 6 months.  
The Khorana score was derived in a cohort of cancer patients and subsequently externally 
validated [4]. In a recent large meta-analysis including more than 34,000 patients, the score was able 
to identify a group of patients with a higher risk of VTE (odds ratio 1.8 for high vs. lower risk); 
however, patients classified as being at low (0 points) or intermediate risk (1 or 2 points) had an 
incidence of VTE that was as high as 5.1% and 6.6%, respectively [10]. Consistently, we found an 
incidence of 6% in patients with a Khorana score below 3 points. Interestingly, the performance of 
the Khorana as well as all other scores seemed to improve substantially at a positivity threshold of 2 
points as evidenced by the identification of a larger proportion of patients who eventually developed 
VTE and the significant difference between high and low risk patients. Although not formally derived 
and validated, the Khorana score at a positivity threshold of 2 points has been used by two recently 
completed randomized trials of primary prophylaxis to select ambulatory cancer patients at high risk 
of VTE [8-9]. Both studies demonstrated that 6-month prophylaxis with apixaban or rivaroxaban 
reduce the incidence of VTE compared with placebo, without significantly increasing the risk of major 
bleeding [8-9]. These trials did not include patients with a Khorana score of 1 point or less in whom 
the incidence of VTE was 4.4% in our study and 5.5% in the abovementioned meta-analysis. These 
observations suggest substantial residual VTE risk and imply that about half of patients with cancer 
who eventually develop VTE may not be candidate for thromboprophylaxis according to the score.  
 Consistent with these findings, a prospective study showed limited ability of multiple 
prediction scores to identify the majority of cancer patients developing VTE [7]. Failures to replicate 
initial findings and variations in risk score performance could stem from differences in patient 
populations, clinical settings, or time periods [10]. In addition, in a pooled analysis of two large 
cohorts, only tumor type was predictive of VTE, while all other components of the Khorana score 
were not associated with the development of VTE [20]. In the current study, multivariable analysis 
confirmed that tumor type is the only predictor of VTE in the Khorana score, though this association 
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did not reach statistical significance. This finding likely depends on the relatively low number of 
patients with high-risk tumor as well as the inclusion of tumor types that were infrequent in the 
derivation study, though shown to be associated with a higher risk of VTE in subsequent analyses 
[7,20]. Taken together, current evidence from cohort studies, a subsequent large meta-analysis, as 
well as two recently published randomized clinical trials support the use of a risk stratification 
strategy to select cancer patients for thromboprophylaxis. However, future studies should evaluate 
ways to improve efficiency of risk stratification to reduce the proportion of patients with VTE who 
are erroneously classified as at low risk. 
Preliminary observations suggest that the accuracy of most scores for VTE prediction in 
cancer patients decreases during the first weeks of follow-up [7]. In time-dependent analysis, the 
modest scores’ performance tended to decrease further beyond the initial 3 to 6 months, which 
could partly depend on VTE risk factors not present at baseline yet emerging during the dynamic 
cancer journey. In addition, most components of the risk scores including body weight, performance 
status, and blood counts often fluctuate during the course of cancer disease because of cancer 
treatment, co-morbidities, or cancer progression. As a result, the importance of these variables is 
highly contingent to the time they are evaluated and may change over time potentially affecting risk 
stratification and long-term predictive value of the score. Therefore, in the present study, all scores 
were re-calculated after the first 3 months to assess the impact of these changes between the 
follow-up score relative to baseline. While the discriminatory performance of the score calculated at 
follow-up remained poor, the relatively low number of events beyond 3 to 6 months hampers firm 
conclusions.  
 The present retrospective study including various tumor types and using laboratory data 
collected before start of chemotherapy is one of the largest comparisons of multiple prediction 
scores for cancer-associated VTE. There are some limitations that need to be acknowledged. The 
collection of data at pre-specified time points for evaluation of the re-assessed scores was limited. 
However, the proportion of patients in whom the scores could not be calculated at follow-up was 
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lower than 2%. Second, the single-center design of the study may limit the external validity of the 
findings. Third, we could not evaluate the CATS score, since D-dimer and soluble P-selectin levels are 
not available in routine clinical practice, nor the extensive COMPASS-CAT score, because data on 
cardiovascular risk factors were not available. Fourth, the number of events may not have provided 
enough power to detect significant differences, especially in the multivariable analyses and analyses 
of the re-assessed scores. 
In summary, the current study confirms that the Khorana, PROTECHT, CONKO, and ONKOTEV 
scores do not own sufficient accuracy to select patients for pharmacological thromboprophylaxis 
when used at a conventional positivity threshold of 3 points. Although performance of all scores was 
improved with the use of a positivity threshold of 2 points, incidence of VTE in patients classified as 
at low risk of VTE is not negligible. Score accuracy tends to decrease over time suggesting the need of 
periodic re-evaluation to estimate changes in patient's risk.  
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Table 1. Patient characteristics 
 N=776 
Age, y, mean (SD) 65 (11) 
Male sex, n (%) 471 (61) 
Body mass index, kg/m2  
   Mean (SD) 26 (4.6) 
   ≥35 kg/m2, n (%) 35 (4.5) 
Tumor type, n (%)  
   Lung cancer 277 (36) 
   Colorectal 224 (29) 
   Gynecological 88 (11) 
   Pancreatic 71 (9.1) 
   Stomach 58 (7.5) 
   Urogenital 37 (4.8) 
   Hepatobiliary 21 (2.7) 
Distant metastasis, n (%) 540 (70) 
WHO performance status, n (%)  
   0 510 (66) 
   1 226 (29) 
   ≥2 37 (4.8) 
   Missing 3 (0.4) 
Vascular compression or infiltration, n (%) 47 (6.1) 
Chemotherapy, n (%)  
   Platinum-based 413 (53) 
   Gemcitabin 105 (14) 
   Other 153 (20) 
   Missing 7 (0.9) 
Central venous catheter, n (%) 51 (6.6) 
Surgery in previous 4 weeks, n (%) 137 (18) 
Previous venous thromboembolism, n (%) 6 (0.8) 
Erythropoietin stimulating agents, n (%) 20 (2.6) 
Hemoglobin, g/dL  
   Median (IQR) 13 (11-14) 
   <10 g/dL, n (%) 48 (6.2) 
White blood cell count, x 109/L  
   Median (IQR) 7.0 (5.5-9.2) 
   >11 x 109/L, n (%) 104 (13) 
Platelet count, x 109/L  
   Median (IQR) 258 (198-332) 
   ≥350 x 109/L, n (%) 162 (21) 
Abbreviations: IQR, interquartile range; SD, standard deviation.
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Table 2. Distribution of risk scores 
 Baseline scores (N=776) Re-assessed scores (N=606) 
 Khorana PROTECHT CONKO ONKOTEV Khorana  PROTECHT CONKO ONKOTEV 
Points, n (%)         
  0  172 (22) 65 (8.4) 174 (22) 150 (19) 168 (28) 149 (25) 166 (27) 99 (16) 
  1  287 (37) 145 (19) 285 (37) 355 (46) 213 (35) 217 (36) 222 (37) 304 (50) 
  2  218 (28) 228 (29) 211 (27) 235 (30) 155 (26) 146 (24) 144 (24) 172 (28) 
  3  76 (9.8) 211 (27) 80 (10) 20 (2.6) 51 (8.4) 64 (11) 54 (8.9) 18 (3.0) 
  4  13 (1.7) 87 (11) 14 (1.8) 0 9 (1.5) 18 (3.0) 9 (1.5) 0 
  5  1 (0.1) 21 (2.7) 1 (0.1) - 1 (0.2) 2 (0.3) 2 (0.3) - 
  6 0 3 (0.4) 0 - 0 1 (0.2) 0 - 
  Missing 9 (1.2) 16 (2.1) 11 (1.4) 16 (2.1) 9 (1.5) 9 (1.5) 9 (1.5) 13 (2.1) 
Positivity threshold 3 points, n (%)         
  Low risk (≤2 points) 678 (87) 438 (56) 670 (86) 740 (95) 536 (88) 512 (85) 532 (88) 575 (95) 
  High risk (≥3 points) 89 (12) 322 (42) 95 (12) 20 (2.6) 61 (10) 85 (14) 65 (11) 18 (3.0) 
Positivity threshold 2 points, n (%)         
  Low risk (≤1 points) 460 (59) 210 (27) 459 (59) 505 (65) 381 (63) 366 (60) 388 (64) 403 (67) 
  High risk (≥2 points) 307 (40) 550 (71) 306 (39) 255 (33) 216 (36) 231 (38) 209 (35) 190 (31) 
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Table 3. Performance of the risk scores for deep vein thrombosis or pulmonary embolism at the positivity threshold of 3 and 2 points 
 
  Khorana score PROTECHT score CONKO score ONKOTEV score 
Time-dependent c-index (95% CI)     
   At 90 days  0.63 (0.55-0.71) 0.63 (0.55-0.72) 0.61 (0.54-0.69) 0.62 (0.51-0.74) 
   At 180 days 0.61 (0.56-0.66) 0.61 (0.55-0.66) 0.60 (0.54-0.66) 0.59 (0.52-0.66) 
   At 365 days  0.59 (0.54-0.65) 0.57 (0.51-0.63) 0.59 (0.53-0.65) 0.57 (0.50-0.64) 
 3-point 
threshold 
2-point 
threshold 
3-point 
threshold 
2-points 
threshold 
3-point 
threshold 
2-points 
threshold 
3-point 
threshold 
2-points 
threshold 
6-month follow-up         
   VTE risk in low risk patients, % 
(95% CI) 
6.0 (4.4-8.0) 4.4 (2.8-6.6) 4.4 (2.8-6.7) 0.50 (0.04-2.5) 5.9 (4.3-7.9) 4.7 (3.0-6.9) 5.4 (3.9-7.2) 4.8 (3.2-7.0) 
   VTE risk in high risk patients, % 
(95% CI) 
3.5 (0.9-9.1) 7.7 (5.0-11) 7.6 (5.0-11) 7.8 (5.7-10) 4.4 (1.4-10) 7.3 (4.7-11) 15 (3.5-34) 7.2 (4.4-11) 
   SHR for high vs low risk 
patients  
0.58 (0.18-
0.87) 
1.8 (0.98-
3.3) 
1.8 (0.97-3.2) 17 (2.3-122) 0.73 (0.26-2.1) 1.6 (0.89-3.0) 3.0 (0.91-10) 1.5 (0.83-2.8) 
12-month follow-up         
   VTE risk in low risk patients, % 
(95% CI) 
7.6 (5.7-9.8) 5.9 (3.9-8.3) 6.2 (4.2-8.8) 2.1 (0.68-4.9) 7.6 (5.7-9.8) 6.1 (4.1-8.6) 6.9 (5.2-8.9) 6.6 (4.6-9.1) 
   VTE risk in high risk patients, % 
(95% CI) 
4.8 (1.5-11) 9.4 (6.4-13) 8.6 (5.8-12) 9.2 (6.9-12) 5.5 (2.0-12) 9.1 (6.2-13) 20 (5.9-40) 8.5 (5.4-12) 
   SHR for high vs low risk 
patients  
0.62 (0.22-1.7) 1.74 (0.99-
2.9) 
4.5 (0.85-2.5) 4.9 (1.8-14) 0.73 (0.29-1.8) 1.6 (0.91-2.6) 3.2 (1.2-9.1) 1.3 (0.77-2.3) 
 
Abbreviations: VTE, venous thromboembolism; SHR, subdistribution hazard. 
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Abstract 
The long-term performance of prediction scores for venous thromboembolism (VTE) in cancer 
patients has been poorly investigated. We evaluated the discriminatory performance of the Khorana, 
PROTECHT, CONKO, and ONKOTEV scores for the first 3-6 months and for 12 months, and re-
assessed scores after 3-6 months to determine the influence of variations in patients' risk 
classification on performance.  
Retrospective cohort of ambulatory patients with active cancer who were scheduled to receive first 
or new line of chemotherapy. The primary outcome was symptomatic or incidental VTE. 
A total of 776 patients were included of whom 540 (70%) had distant metastases. The time-
dependent c-statistics of Khorana, PROTECHT, CONKO, and ONKOTEV scores at 6 months were 0.61 
(95% CI, 0.56 to 0.66), 0.61 (95% CI, 0.55 to 0.66), 0.60 (95% CI, 0.54 to 0.66), and 0.59 (0.52 to 0.66), 
respectively, with a tendency to decrease during follow-up. None of the scores discriminated 
between high and low risk patients at the conventional 3-point positivity threshold. The use of a 2-
point positivity threshold improved performance of all scores and captured a higher proportion of 
VTE. The accuracy of risk scores re-assessed at 3-6 months was modest. 
The Khorana, PROTECHT, CONKO, and ONKOTEV scores are not sufficiently accurate when used at a 
conventional threshold of 3 points. Performance improves at positivity threshold of 2 points, as 
evaluated in recent randomized studies on VTE prophylaxis. Score accuracy tends to decrease over 
time suggesting the need of periodic re-evaluation to estimate possible variation of risk.  
 
 
Keywords: neoplasms, venous thrombosis, venous thromboembolism, predictive value of tests, 
biomarkers 
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Key points 
 VTE is a frequent complication in patients with cancer, but most of these patients will not 
develop thrombosis during the course of their disease 
 Prediction scores have been developed to identify cancer patients at higher risk of VTE in 
whom the benefits of thromboprophylaxis would not be offset by the risk of bleeding 
 At the conventional 3-point threshold, the Khorana, PROTECHT, CONKO, and ONKOTEV 
scores perform poorly  
 Performance improves at 2-point positivity threshold, but residual VTE risk remains 
substantial 
 Score accuracy decreases over time suggesting the need of periodic re-evaluation  
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Introduction 
Although venous thromboembolism (VTE) represents a frequent complication in patients with cancer 
undergoing chemotherapy, most of these patients will not develop thrombosis during the course of 
their disease [1-2]. Therefore, broad, routine use of pharmacological thromboprophylaxis would 
unnecessarily expose most of these patients to burdensome long-term subcutaneous heparin 
administration as well as to the risk of anticoagulant-related bleeding [3].  
Several studies have attempted to identify cancer patients at higher risk of VTE in whom the 
benefits of thromboprophylaxis would not be offset by the risk of bleeding [4-5]. One of the most 
extensively evaluated VTE risk stratification tools for cancer patients is the score developed by 
Khorana and colleagues, which is calculated by assigning points to the type of tumor, low hemoglobin 
level or use of erythropoietic agents, high body mass index, and high platelet or white blood cell 
count (Supplementary Table 1) [6]. In the derivation study including over 3,000 ambulatory cancer 
patients, the score identified a high-risk group in whom the incidence of VTE was 7% during a mean 
follow-up of 3 months. These findings were replicated in a number of external cohort studies [4,7]. 
Similarly, two recent randomized clinical trials of pharmacological prophylaxis including cancer 
patients at high risk of VTE according to the Khorana score reported a VTE incidence of around 10% 
in patients receiving placebo, which support the use of this score to identify patients at risk of VTE [8-
9]. In contrast, in a large meta-analysis of over 34,000 cancer patients, the incidence of VTE in low or 
intermediate risk groups according to the Khorana score was not negligible, and over half of the 
patients who ultimately developed cancer-associated VTE did not qualify for thromboprophylaxis 
based on their risk score profile [10]. Patients with a low Khorana score were not randomized nor 
prospectively followed in the two recent randomized studies, which leaves unclear how many 
eventually experienced VTE [8-9].  
Efforts have been made to increase the performance of the Khorana score or derive new 
prediction models. For example, the Khorana score could be improved by adding measurement of D-
dimer and soluble P-selectin [11], adding use of gemcitabine or platinum compounds [12], by 
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replacing body mass index with functional status [13], and by adding metastatic disease, vascular 
compression, and previous VTE to the dichotomized Khorana score (Supplementary Table 1)[14]. 
Nonetheless, a recent prospective validation study with 6-month follow-up found that the 
performance of most of these scores was still suboptimal as indicated by low c-statistics [7]. In 
addition, the accuracy of prediction tools for VTE in cancer patients over follow-up periods longer 
than 3 to 6 months has been poorly investigated. Preliminary observations suggest that performance 
decreases after the first weeks of follow-up [7]. Since all these scores include parameters that can 
vary over time, this may ultimately result in changes of patients' risk classification and score 
performance. 
The aims of this study were to compare the discriminatory performance of the Khorana, 
PROTECHT, CONKO, and ONKOTEV scores for the first 3 to 6 months versus 12 months of follow-up, 
and to re-assess all scores after 3 to 6 months to determine variations of patients' risk classification 
and performance of the follow-up score compared to the score calculated at start of chemotherapy. 
In addition, we validated the long-term accuracy of the scores at a 2-point positivity threshold, as 
used in recently completed randomized studies on VTE prophylaxis in patients with cancer [8-9]. 
 
Materials and Methods 
Study population 
We conducted a single-center, retrospective cohort study of patients with recurrent, regionally 
advanced, or metastatic cancer in whom the Khorana, PROTECHT, CONKO, and ONKOTEV scores 
were calculated before the start of a first or new line of chemotherapy. Exclusion criteria were 
ongoing anticoagulant treatment for VTE diagnosed prior to start of chemotherapy or for other 
indications, or use of outpatient thromboprophylaxis during the study. The study was approved by 
the local institutional review board. 
 
Study Outcomes 
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The primary outcome of the study was symptomatic or incidental VTE, defined as distal or proximal 
deep vein thrombosis (DVT) of the leg, upper extremity DVT, and/or pulmonary embolism (PE) [15]. 
Incidental VTE was defined as VTE detected by imaging tests performed for other reasons than VTE 
suspicion, such as assessment of response to cancer treatment, cancer re-staging or the diagnostic 
work-up of cancer-related complications [16]. 
Secondary outcomes were major bleeding, clinically relevant non-major bleeding, arterial 
thromboembolism, superficial vein thrombosis, and overall mortality [17-18]. 
 
Statistical considerations 
Standard descriptive statistics were used to summarize patient characteristics. We calculated the 
Khorana, PROTECHT, CONKO, and ONKOTEV score before start of chemotherapy and after 3 to 6 
months. Tumor sites were categorized into “low/intermediate”, “high”, and “very-high” risk of VTE 
according to the Khorana score [6]. Patients were followed for the development of VTE up to 1 year 
since the start of chemotherapy. The Khorana score was assessed at the conventional positivity 
threshold of 3 points as well as at the exploratory 2-point threshold. We also evaluated the 
performance of the PROTECT, CONKO, and ONKOTEV scores which are modifications of the Khorana 
score (Supplementary Table 1) [12-14]. We could not assess the CATS score since D-dimer and 
soluble P-selectin are not measured routinely [11] nor the extensive COMPASS-CAT score because 
data on cardiovascular risk factors were not available [19]. 
 Overall discrimination of the scores for PE and/or DVT was assessed with a time-dependent 
c-statistic, while accounting for death not related to VTE as a competing risk (R package concreg). The 
95% confidence intervals were estimated by repeating the analyses in 250 bootstrap samples. The 
cumulative incidence in patients with a high and low risk score was estimated using the cumulative 
incidence function with 95% confidence intervals calculated using Choudhury’s method, considering 
death not related to VTE as a competing risk. Differences between high and low risk patients were 
quantified by calculating subdistribution hazard ratios (SHRs) based on the competing risk regression 
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model of Fine & Gray (R package cmprsk). A multivariable Fine & Gray model was used to assess the 
association of the individual score items with VTE. A sensitivity analysis restricted to symptomatic 
events was performed. Since the proportion of patients for whom the scores could not be calculated 
was low (<3%), we did not use multiple imputation methods. Analyses were performed in R, version 
3.4.4 (R Foundation for Statistical Computing, Vienna, Austria). 
 
Results 
Between January 2011 and July 2017, 887 potentially eligible cancer patients were identified of 
whom 111 (12.5%) were excluded because of ongoing anticoagulant treatment for VTE (N=63), atrial 
fibrillation (N=37), or mechanical heart valve (N=2), or because they did not attend oncological 
follow-up visits after the initial evaluation due to rapid cancer progression (N=48). Baseline 
characteristics of the remaining 776 patients are summarized in Table 1. Mean age was 65 years and 
61% was male. The most frequent tumor types were non-small lung cancer (29%), colorectal cancer 
(29%), and gynecological cancer (11%). The distribution of the risk scores at baseline and at follow-up 
re-assessment is shown in Table 2. 
 
Follow-up and outcomes 
The median overall follow-up duration was 330 days (interquartile range [IQR], 159 to 365). Overall, 
69 patients (8.9%) developed a thrombotic event which was DVT in 28 (3.6%), PE in 20 (2.6%), 
splanchnic DVT in 10 (1.3%), PE with DVT in 6 (0.8%), superficial vein thrombosis in 3 (0.4%), and 
arterial thrombosis in 2 (0.3%). Of the 54 PE, DVT, and PE with DVT, 27 events (50%) were 
symptomatic. The 3-, 6-, and 12-month cumulative incidences of PE and/or DVT in the competing risk 
analysis were 2.8% (95% CI, 1.8 to 4.2), 5.6% (95% CI, 4.2 to 7.4), and 7.2% (95% CI, 5.5 to 9.2), 
respectively. The median time to PE and/or DVT was 104 days (95% CI, 64 to 172). During follow-up, 
343 patients (44%) died and 5 (0.6%) were lost to follow-up. 
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Performance of baseline risk scores  
The overall discriminatory performance of the baseline scores for PE and/or DVT is shown in Table 3. 
The time-dependent c-statistics of the Khorana, PROTECHT, CONKO, and ONKOTEV scores at 180 
days were 0.61 (95% CI, 0.56 to 0.66), 0.61 (95% CI, 0.55 to 0.66), 0.60 (95% CI, 0.54 to 0.66), and 
0.59 (0.52 to 0.66), respectively (Supplementary Figures 1A-D). The sensitivity analysis restricted to 
symptomatic events yielded comparable results (c-statistics 0.63, 0.62, 0.62, and 0.56 for the 
Khorana, PROTECHT, CONKO, and ONKOTEV scores, respectively). 
Using the conventional positivity threshold of 3 points, the Khorana, PROTECHT, CONKO, and 
ONKOTEV scores classified 12%, 42%, 12%, and 2.6% of patients as high risk (Table 2). The cumulative 
incidence of VTE at 6 months in these high-risk patients was 3.5%, 7.6%, 4.4%, and 15% respectively, 
compared to 6.0%, 4.4%, 5.9%, and 5.4% in the low risk groups. The corresponding SHRs for high vs. 
low risk were 0.58 (95% CI, 0.18 to 0.87), 1.8 (95% CI, 0.98 to 3.3), 0.73 (95% CI, 0.26 to 2.1), and 3.0 
(95% CI, 0.91 to 10) for the Khorana, PROTECHT, CONKO, and ONKOTEV scores, respectively (Figures. 
1A-D). Data for the 12-month study period are presented in Table 3. 
Using the alternative positivity threshold of 2 points, the Khorana, PROTECHT, CONKO, and 
ONKOTEV scores classified 40%, 71%, 39%, and 33% of patients as high risk (Table 2). In these high-
risk groups, the cumulative incidences of PE or DVT at 6 months were 7.7%, 7.8%, 7.3%, and 7.2% 
compared to 4.4%, 0.5%, 4.7%, and 4.8% in patients with a low risk score, respectively. The 
corresponding SHRs for high vs. low risk patients were 1.8 (95% CI, 0.98 to 3.3), 17 (95% CI, 2.3 to 
122), 1.6 (95% CI, 0.89 to 3.0), and 1.5 (95% CI, 0.83 to 2.8) for the Khorana, PROTECHT, CONKO, and 
ONKOTEV scores, respectively (Figures 2A-D). 
In multivariable competing risk analyses, all score items except high platelet count had a 
positive association with PE and/or DVT at 6 months (Supplementary Table 2). The only items that 
met statistical significance were platinum-based chemotherapy in the PROTECHT score (SHR 2.5; 95% 
CI, 1.1 to 6.1) and previous VTE in the ONKOTEV score (SHR 17; 95% CI, 5.2 to 52). 
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Performance of risk scores re-assessed at 3 to 6 months 
Re-assessment of the risk scores was done in 606 of 618 patients who were alive and without 
thrombosis (98%) at a median follow-up of 158 days (IQR, 113 to 179). From this re-assessment until 
the end of follow-up, 15 patients (2.5%) developed a thrombotic event of which 12 events (2.0%) 
were PE and/or DVT. At the conventional positivity threshold of 3 points, the re-assessed Khorana, 
PROTECHT, CONKO, and ONKOTEV scores re-classified 12%, 32%, 12%, and 1% of patients, 
respectively (Supplementary Tables 3A-D). Overall, 10%, 14%, 11%, and 3% of patients were classified 
as being at high risk by the re-assessed Khorana, PROTECHT, CONKO, and ONKOTEV scores. The 
cumulative incidence of PE or DVT at 180 days after re-assessment was 3.3%, 2.4%, 3.0%, and 5.6% in 
patients with a high-risk Khorana, PROTECHT, CONKO, and ONKOTEV score, respectively 
(Supplementary Table 4). These numbers were 1.9%, 2.0%, 1.9%, and 0.70% in those with a low risk 
score, corresponding to SHRs of 1.8 (95% CI, 0.38 to 8.0), 1.2% (95% CI, 0.26 to 5.5), 1.6 (95% CI, 0.34 
to 7.1), and 8.1 (95% CI, 0.93 to 71), respectively.  
 
DISCUSSION 
This study confirms the poor overall discriminatory performance of the Khorana, PROTECHT, CONKO, 
and ONKOTEV scores for the prediction of DVT or PE in patients with cancer receiving chemotherapy. 
When used dichotomously, none of the scores was able to identify a group of patients with a 
significantly higher risk of VTE. Yet, the use of a lower positivity threshold of 2 points was associated 
with improved performance of all scores, but in particular the PROTECHT and CONKO scores. Time-
dependent analysis suggested that scores’ discrimination tends to decrease during follow-up, with 
limited or no value of the scores beyond the first 3 to 6 months. Re-evaluation of the four scores at 3 
to 6 months changed the indication for pharmacological thromboprophylaxis in 12% up to 32% of 
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patients, but the use of a re-assessed score is questionable because of the low risk of DVT or PE in 
the following 6 months.  
The Khorana score was derived in a cohort of cancer patients and subsequently externally 
validated [4]. In a recent large meta-analysis including more than 34,000 patients, the score was able 
to identify a group of patients with a higher risk of VTE (odds ratio 1.8 for high vs. lower risk); 
however, patients classified as being at low (0 points) or intermediate risk (1 or 2 points) had an 
incidence of VTE that was as high as 5.1% and 6.6%, respectively [10]. Consistently, we found an 
incidence of 6% in patients with a Khorana score below 3 points. Interestingly, the performance of 
the Khorana as well as all other scores seemed to improve substantially at a positivity threshold of 2 
points as evidenced by the identification of a larger proportion of patients who eventually developed 
VTE and the significant difference between high and low risk patients. Although not formally derived 
and validated, the Khorana score at a positivity threshold of 2 points has been used by two recently 
completed randomized trials of primary prophylaxis to select ambulatory cancer patients at high risk 
of VTE [8-9]. Both studies demonstrated that 6-month prophylaxis with apixaban or rivaroxaban 
reduce the incidence of VTE compared with placebo, without significantly increasing the risk of major 
bleeding [8-9]. These trials did not include patients with a Khorana score of 1 point or less in whom 
the incidence of VTE was 4.4% in our study and 5.5% in the abovementioned meta-analysis. These 
observations suggest substantial residual VTE risk and imply that about half of patients with cancer 
who eventually develop VTE may not be candidate for thromboprophylaxis according to the score.  
 Consistent with these findings, a prospective study showed limited ability of multiple 
prediction scores to identify the majority of cancer patients developing VTE [7]. Failures to replicate 
initial findings and variations in risk score performance could stem from differences in patient 
populations, clinical settings, or time periods [10]. In addition, in a pooled analysis of two large 
cohorts, only tumor type was predictive of VTE, while all other components of the Khorana score 
were not associated with the development of VTE [20]. In the current study, multivariable analysis 
confirmed that tumor type is the only predictor of VTE in the Khorana score, though this association 
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did not reach statistical significance. This finding likely depends on the relatively low number of 
patients with high-risk tumor as well as the inclusion of tumor types that were infrequent in the 
derivation study, though shown to be associated with a higher risk of VTE in subsequent analyses 
[7,20]. Taken together, current evidence from cohort studies, a subsequent large meta-analysis, as 
well as two recently published randomized clinical trials support the use of a risk stratification 
strategy to select cancer patients for thromboprophylaxis. However, future studies should evaluate 
ways to improve efficiency of risk stratification to reduce the proportion of patients with VTE who 
are erroneously classified as at low risk. 
Preliminary observations suggest that the accuracy of most scores for VTE prediction in 
cancer patients decreases during the first weeks of follow-up [7]. In time-dependent analysis, the 
modest scores’ performance tended to decrease further beyond the initial 3 to 6 months, which 
could partly depend on VTE risk factors not present at baseline yet emerging during the dynamic 
cancer journey. In addition, most components of the risk scores including body weight, performance 
status, and blood counts often fluctuate during the course of cancer disease because of cancer 
treatment, co-morbidities, or cancer progression. As a result, the importance of these variables is 
highly contingent to the time they are evaluated and may change over time potentially affecting risk 
stratification and long-term predictive value of the score. Therefore, in the present study, all scores 
were re-calculated after the first 3 months to assess the impact of these changes between the 
follow-up score relative to baseline. While the discriminatory performance of the score calculated at 
follow-up remained poor, the relatively low number of events beyond 3 to 6 months hampers firm 
conclusions.  
 The present retrospective study including various tumor types and using laboratory data 
collected before start of chemotherapy is one of the largest comparisons of multiple prediction 
scores for cancer-associated VTE. There are some limitations that need to be acknowledged. The 
collection of data at pre-specified time points for evaluation of the re-assessed scores was limited. 
However, the proportion of patients in whom the scores could not be calculated at follow-up was 
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lower than 2%. Second, the single-center design of the study may limit the external validity of the 
findings. Third, we could not evaluate the CATS score, since D-dimer and soluble P-selectin levels are 
not available in routine clinical practice, nor the extensive COMPASS-CAT score, because data on 
cardiovascular risk factors were not available. Fourth, the number of events may not have provided 
enough power to detect significant differences, especially in the multivariable analyses and analyses 
of the re-assessed scores. 
In summary, the current study confirms that the Khorana, PROTECHT, CONKO, and ONKOTEV 
scores do not own sufficient accuracy to select patients for pharmacological thromboprophylaxis 
when used at a conventional positivity threshold of 3 points. Although performance of all scores was 
improved with the use of a positivity threshold of 2 points, incidence of VTE in patients classified as 
at low risk of VTE is not negligible. Score accuracy tends to decrease over time suggesting the need of 
periodic re-evaluation to estimate changes in patient's risk.  
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Table 1. Patient characteristics 
 N=776 
Age, y, mean (SD) 65 (11) 
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Male sex, n (%) 471 (61) 
Body mass index, kg/m2  
   Mean (SD) 26 (4.6) 
   ≥35 kg/m2, n (%) 35 (4.5) 
Tumor type, n (%)  
   Lung cancer 277 (36) 
   Colorectal 224 (29) 
   Gynecological 88 (11) 
   Pancreatic 71 (9.1) 
   Stomach 58 (7.5) 
   Urogenital 37 (4.8) 
   Hepatobiliary 21 (2.7) 
Distant metastasis, n (%) 540 (70) 
WHO performance status, n (%)  
   0 510 (66) 
   1 226 (29) 
   ≥2 37 (4.8) 
   Missing 3 (0.4) 
Vascular compression or infiltration, n (%) 47 (6.1) 
Chemotherapy, n (%)  
   Platinum-based 413 (53) 
   Gemcitabin 105 (14) 
   Other 153 (20) 
   Missing 7 (0.9) 
Central venous catheter, n (%) 51 (6.6) 
Surgery in previous 4 weeks, n (%) 137 (18) 
Previous venous thromboembolism, n (%) 6 (0.8) 
Erythropoietin stimulating agents, n (%) 20 (2.6) 
Hemoglobin, g/dL  
   Median (IQR) 13 (11-14) 
   <10 g/dL, n (%) 48 (6.2) 
White blood cell count, x 109/L  
   Median (IQR) 7.0 (5.5-9.2) 
   >11 x 109/L, n (%) 104 (13) 
Platelet count, x 109/L  
   Median (IQR) 258 (198-332) 
   ≥350 x 109/L, n (%) 162 (21) 
Abbreviations: IQR, interquartile range; SD, standard deviation.
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Table 2. Distribution of risk scores 
 Baseline scores (N=776) Re-assessed scores (N=606) 
 Khorana PROTECHT CONKO ONKOTEV Khorana  PROTECHT CONKO ONKOTEV 
Points, n (%)         
  0  172 (22) 65 (8.4) 174 (22) 150 (19) 168 (28) 149 (25) 166 (27) 99 (16) 
  1  287 (37) 145 (19) 285 (37) 355 (46) 213 (35) 217 (36) 222 (37) 304 (50) 
  2  218 (28) 228 (29) 211 (27) 235 (30) 155 (26) 146 (24) 144 (24) 172 (28) 
  3  76 (9.8) 211 (27) 80 (10) 20 (2.6) 51 (8.4) 64 (11) 54 (8.9) 18 (3.0) 
  4  13 (1.7) 87 (11) 14 (1.8) 0 9 (1.5) 18 (3.0) 9 (1.5) 0 
  5  1 (0.1) 21 (2.7) 1 (0.1) - 1 (0.2) 2 (0.3) 2 (0.3) - 
  6 0 3 (0.4) 0 - 0 1 (0.2) 0 - 
  Missing 9 (1.2) 16 (2.1) 11 (1.4) 16 (2.1) 9 (1.5) 9 (1.5) 9 (1.5) 13 (2.1) 
Positivity threshold 3 points, n (%)         
  Low risk (≤2 points) 678 (87) 438 (56) 670 (86) 740 (95) 536 (88) 512 (85) 532 (88) 575 (95) 
  High risk (≥3 points) 89 (12) 322 (42) 95 (12) 20 (2.6) 61 (10) 85 (14) 65 (11) 18 (3.0) 
Positivity threshold 2 points, n (%)         
  Low risk (≤1 points) 460 (59) 210 (27) 459 (59) 505 (65) 381 (63) 366 (60) 388 (64) 403 (67) 
  High risk (≥2 points) 307 (40) 550 (71) 306 (39) 255 (33) 216 (36) 231 (38) 209 (35) 190 (31) 
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Table 3. Performance of the risk scores for deep vein thrombosis or pulmonary embolism at the positivity threshold of 3 and 2 points 
 
  Khorana score PROTECHT score CONKO score ONKOTEV score 
Time-dependent c-index (95% CI)     
   At 90 days  0.63 (0.55-0.71) 0.63 (0.55-0.72) 0.61 (0.54-0.69) 0.62 (0.51-0.74) 
   At 180 days 0.61 (0.56-0.66) 0.61 (0.55-0.66) 0.60 (0.54-0.66) 0.59 (0.52-0.66) 
   At 365 days  0.59 (0.54-0.65) 0.57 (0.51-0.63) 0.59 (0.53-0.65) 0.57 (0.50-0.64) 
 3-point 
threshold 
2-point 
threshold 
3-point 
threshold 
2-points 
threshold 
3-point 
threshold 
2-points 
threshold 
3-point 
threshold 
2-points 
threshold 
6-month follow-up         
   VTE risk in low risk patients, % 
(95% CI) 
6.0 (4.4-8.0) 4.4 (2.8-6.6) 4.4 (2.8-6.7) 0.50 (0.04-2.5) 5.9 (4.3-7.9) 4.7 (3.0-6.9) 5.4 (3.9-7.2) 4.8 (3.2-7.0) 
   VTE risk in high risk patients, % 
(95% CI) 
3.5 (0.9-9.1) 7.7 (5.0-11) 7.6 (5.0-11) 7.8 (5.7-10) 4.4 (1.4-10) 7.3 (4.7-11) 15 (3.5-34) 7.2 (4.4-11) 
   SHR for high vs low risk 
patients  
0.58 (0.18-
0.87) 
1.8 (0.98-
3.3) 
1.8 (0.97-3.2) 17 (2.3-122) 0.73 (0.26-2.1) 1.6 (0.89-3.0) 3.0 (0.91-10) 1.5 (0.83-2.8) 
12-month follow-up         
   VTE risk in low risk patients, % 
(95% CI) 
7.6 (5.7-9.8) 5.9 (3.9-8.3) 6.2 (4.2-8.8) 2.1 (0.68-4.9) 7.6 (5.7-9.8) 6.1 (4.1-8.6) 6.9 (5.2-8.9) 6.6 (4.6-9.1) 
   VTE risk in high risk patients, % 
(95% CI) 
4.8 (1.5-11) 9.4 (6.4-13) 8.6 (5.8-12) 9.2 (6.9-12) 5.5 (2.0-12) 9.1 (6.2-13) 20 (5.9-40) 8.5 (5.4-12) 
   SHR for high vs low risk 
patients  
0.62 (0.22-1.7) 1.74 (0.99-
2.9) 
4.5 (0.85-2.5) 4.9 (1.8-14) 0.73 (0.29-1.8) 1.6 (0.91-2.6) 3.2 (1.2-9.1) 1.3 (0.77-2.3) 
 
Abbreviations: VTE, venous thromboembolism; SHR, subdistribution hazard. 
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Figure 1 - A-D. Discrimination of dichotomized risk scores at 3-point positivity threshold 
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Figure 2 - A-D. Discrimination of dichotomized risk scores at 2-point positivity threshold 
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